Novaliq begins phase II dry eye trial

Friday, February 19, 2016

Novaliq, a pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, has begun enrolling patients in a phase II clinical trial that will evaluate the safety, efficacy and tolerability of CyclASol for the treatment of moderate to severe dry eye disease (DED). CyclASol is a clear, preservative free ophthalmic solution of cyclosporine in SFA (semifluorinated alkanes).

[Read More]